HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

atazanavir (Reyataz)

structure in first source

Also Known As:

Reyataz; 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester; BMS 232632; BMS-232632; BMS-232632-05; BMS232632; CGP 73547; CGP 75136; CGP 75176; CGP 75355; CGP-73547; CGP-75136; CGP-75176; CGP-75355; CGP75136; CGP75176; CGP75355; atazanavir sulfate

Networked: 305 relevant articles (13 outcomes, 43 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	McGrath, Donnie: 10 articles (04/2014 - 02/2008)
2.	Daar, Eric S: 9 articles (12/2014 - 12/2009)
3.	Sax, Paul E: 8 articles (12/2014 - 12/2009)
4.	Tierney, Camlin: 7 articles (03/2015 - 12/2009)
5.	Haas, David W: 6 articles (09/2015 - 03/2009)
6.	McComsey, Grace A: 6 articles (08/2015 - 06/2011)
7.	Gathe, Joseph: 6 articles (03/2015 - 09/2011)
8.	Ha, Belinda: 6 articles (03/2015 - 05/2008)
9.	Farajallah, Awny: 6 articles (01/2015 - 12/2009)
10.	Molina, Jean-Michel: 6 articles (03/2014 - 08/2008)

Related Diseases

1.	Hyperlipidemias (Hyperlipidemia) 08/01/2011 - "Switch to atazanavir-containing regimens that were well tolerated resulted in significant improvement of hyperlipidemia and maintenance of clinical, immunologic, and virologic responses to CART." 06/01/2005 - "Switching to atazanavir results in a significant improvement in HIV therapy-induced hyperlipidemia. " 06/01/2009 - "Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir." 08/01/2011 - "In this 48-week prospective, observational study that was conducted at designated hospitals for HIV care in Taiwan, HIV-infected patients aged 18 years or older who had developed hyperlipidemia after receiving CART that did not contain atazanavir were enrolled. " 08/01/2011 - "This study aimed to evaluate the clinical, virologic, and immunologic outcomes in HIV-infected patients with hyperlipidemia whose CART was switched to atazanavir-containing antiretroviral regimens. "
2.	Infection 04/01/2012 - "Atazanavir: in pediatric patients with HIV-1 infection." 05/01/2010 - "Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection." 05/29/2009 - "Atazanavir: a review of its use in the management of HIV-1 infection." 11/01/2006 - "Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection." 12/01/2004 - "Atazanavir for the treatment of human immunodeficiency virus infection."
3.	Lipodystrophy 06/01/2006 - "Intriguingly, atazanavir, a newer PI equally effective against HIV, is associated with fewer signs of lipodystrophy. " 06/01/2006 - "Individual variations in glucuronation may result in differences in serum concentrations of atazanavir, resulting in lipodystrophy, illustrating the difficulty in adjusting dosage. " 01/15/2006 - "Use of atazanavir for 48 weeks neither resulted in abnormal fat redistribution in antiretroviral-naive patients nor induced other metabolic disturbances commonly associated with HIV-related lipodystrophy. " 05/01/2005 - "Lipodystrophy is associated with a low rate of treatment failure in HIV-positive patients switched to atazanavir." 05/01/2004 - "Does atazanavir cause lipodystrophy?"
4.	Acquired Immunodeficiency Syndrome (AIDS) 02/01/2015 - "Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A." 12/01/2014 - "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202." 01/01/2007 - "Over 10 years, patients who started on atazanavir had 30 additional AIDS events per 100 patients. " 04/01/2014 - "We used genomewide genotyping and clinical data to characterize determinants of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. " 04/01/2014 - "Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202."
5.	HIV Infections (HIV Infection) 07/01/2004 - "Data on atazanavir for the treatment of HIV infection are limited to several phase II and III trials, one of which is still ongoing. " 02/01/2015 - "Atazanavir (ATV) is an attractive option for the treatment of Pediatric HIV infection, based on once-daily dosing and the availability of a formulation appropriate for younger children. " 06/18/2012 - "Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use." 02/01/2009 - "Role of atazanavir in the treatment of HIV infection." 01/28/2005 - "Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety."

Related Drugs and Biologics

1.	Ritonavir (Norvir)
2.	lopinavir (Kaletra)
3.	emtricitabine (Emtriva)
4.	tenofovir
5.	Protease Inhibitors (Protease Inhibitor)
6.	efavirenz (Sustiva)
7.	Bilirubin
8.	lamivudine drug combination abacavir
9.	RNA (Ribonucleic Acid)
10.	Nelfinavir (Viracept)

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Stents
3.	Art Therapy
4.	Drug-Eluting Stents
5.	Kidney Transplantation